Trial Profile

Scalable Expanded Access with Analysis of Neurofilament and Other Biomarkers for Ibudilast in ALS

Status: Completed

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 21 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibudilast (Primary)
Indications Amyotrophic lateral sclerosis
Focus Expanded access; Therapeutic Use
Acronyms SEANOBI-ALS

Most Recent Events

18 Aug 2026 Status changed from recruiting to completed.
15 Jul 2026 According to a MediciNova media release, target of enrolling 200 patients in the study has been achieved. Final patient follow-ups are projected to conclude in early 2027.
30 Jan 2026 According to a MediciNova media release, as of the end of January 2026, 12 sites in the US are activated and 100 patients have been enrolled in the SEANOBI study in patients with amyotrophic lateral sclerosis (ALS).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com